scholarly journals VP06.05: Cell‐based non‐invasive FISH diagnosis for Trisomy 21 as a supplement to cell‐free DNA testing: a small pilot series

2020 ◽  
Vol 56 (S1) ◽  
pp. 76-76
Author(s):  
M. Chen
2018 ◽  
Vol 5 (3) ◽  
pp. 139-143
Author(s):  
Sarang Younesi ◽  
Shahram Savad ◽  
Soudeh Ghafouri-Fard ◽  
Mohammad Mahdi Taheri-Amin ◽  
Pourandokht Saadati ◽  
...  

2013 ◽  
Vol 42 (1) ◽  
pp. 41-50 ◽  
Author(s):  
K. H. Nicolaides ◽  
D. Wright ◽  
L. C. Poon ◽  
A. Syngelaki ◽  
M. M. Gil

2015 ◽  
Vol 4 (1) ◽  
pp. 19-22 ◽  
Author(s):  
Kristy Crooks ◽  
Ginger Edwardsen ◽  
Siobhan O'Connor ◽  
Cynthia Powell ◽  
Diane Vargo ◽  
...  

Doctor Ru ◽  
2020 ◽  
Vol 19 (8) ◽  
pp. 49-54
Author(s):  
E.V. Kudryavtseva ◽  
◽  
V.V. Kovalev ◽  
I.I. Baranov ◽  
I.V. Kanivets ◽  
...  

Study Objective: To compare the rates of fetal chromosomal abnormalities (CA) detected during initial non-invasive prenatal DNA testing (NIPT) with the rates of CA found through repeat NIPT in patients with low fetal fraction or low quality of cell-free embryonic DNA. Study Design: This was a retrospective cohort study. Materials and Methods: Twenty-one thousand forty-two women who underwent NIPT in Russia between 2013 and 2018 were included in the study. The main group comprised 1,025 of the 1,044 patients with uninformative results (low fetal fraction result, making it impossible to assess the risk of CA), who consented to repeat NIPT. The control group was made up of 19,998 women who had informative results of initial NIPT. The exclusion group comprised women with low fetal fraction who declined repeat screening. The study method was targeted NIPT. Blood samples were taken from a vein and centrifuged to obtain plasma. Fetal cell-free DNA was analyzed by next-generation sequencing (NGS), a method patented by Natera for sequencing single nucleotide polymorphisms. Study Results: Initial NIPT was uninformative in 1,044 (5%) of the patients and repeat procedure yielded informative results in 821 (80.1%) out of 1,025 patients. Among the patients with informative results from the initial study, the rate of chromosomal aneuploidies was 2.4%. In the group of women with informative results from the repeat procedure, fetal CA were detected in 27 (3.3%) cases. In the subgroup of women with informative results only after a third NIPT, the prevalence of CA was 9.3% (seven out of 75 cases). The study showed that in women carrying fetuses with trisomy 18 or 13 or monosomy X, mean fetal fraction in the first trimester was significantly lower than normal. In the second trimester, significantly lower than normal fetal fraction was observed in women carrying fetuses with trisomy 18 or monosomy X. There was a statistically significant difference in fetal fraction levels between patients with body weight <50 kg and those with body weight 80-89 kg or above (р<0.05). Conclusion: The probability of detecting CA by repeat NIPT is significantly higher than in an initial procedure. If initial testing is not informative, it should be repeated. If the second procedure also fails to yield informative results, invasive prenatal diagnosis should be considered. Fetal fraction levels are lower in heavier women. Thus, other methods of prenatal diagnosis should be recommended for overweight and obese women. Keywords: non-invasive prenatal DNA testing, fetal fraction, prenatal diagnosis, Down syndrome.


OBM Genetics ◽  
2021 ◽  
Vol 05 (03) ◽  
pp. 1-1
Author(s):  
Alison Schmidt ◽  
◽  
Anthony Shanks ◽  

Cell-free DNA has emerged as the most reliable, non-invasive prenatal screening tool for fetal aneuploidies. It has come to replace the previously widely used quadruple screen offered in the second trimester of pregnancy. This change comes with improved detection for aneuploidy but also presents potential gaps in prenatal diagnosis including detection of open fetal defects and emerging data on prediction of adverse pregnancy outcomes. This review article provides a historical summary of the quadruple marker screen and evaluates the intersection of this screen with cell-free DNA. Furthermore, it discusses points to consider as providers trend toward cell-free DNA testing alone and reviews potential options to remedy any disparities.


Sign in / Sign up

Export Citation Format

Share Document